Skip to content

Remimazolam or Ciprofol Combined with Alfentanil for Painless Oocyte Retrieval: A Case–Control Study

Remimazolam or Ciprofol Combined with Alfentanil for Painless Oocyte Retrieval: A Case–Control Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122594
Enrollment
Unknown
Registered
2026-04-15
Start date
2026-02-05
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Remimazolam group (R group) :None
Ciprofol group (C group) :None

Sponsors

Shanghai First Maternity and Infant Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 42 Years

Inclusion criteria

Inclusion criteria: 1. ASA physical status I-II; 2. age 21-42 years; 3. weight 50-77 kg; 4. body mass index (BMI) 18-31 kg/m^2

Exclusion criteria

Exclusion criteria: 1. Uncontrolled blood pressure; 2. Psychiatric disorders; 3. Severe respiratory disease; 4. History of drug abuse or alcohol abuse within 2 years before screening; 5. Use of benzodiazepines and/or opioids for nearly 3 months; 6. Allergy or contraindication to benzodiazepines, opioids, propofol, and their components.

Design outcomes

Primary

MeasureTime frame
Vital signs (BP, HR, SpO2, BIS);Clinical indicators (onset of anesthesia, emergence time, oocyte retrieval duration, postoperative orientation recovery time);Analgesic effect (pain VAS score after ovarian puncture and follicular fluid aspiration);Adverse events (incidence of hypotension, bradycardia, nausea/vomiting, dizziness, respiratory depression);

Secondary

MeasureTime frame
Anesthesia and surgical duration (onset of anesthesia, surgery duration, emergence time);Postoperative recovery quality (orientation recovery time within 30 minutes postoperatively, pain VAS scores at emergence, 15 minutes post-emergence, and 30 minutes post-emergence);Postoperative adverse events (incidence of dizziness, nausea, vomiting);

Countries

China

Contacts

Public ContactLi Haibing

Shanghai First Maternity and Infant Hospital

hiblee@163.com+86 133 7198 5093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026